GlobeImmune Signs CRADA With the National Institutes of Health to Develop...
Marketwire via Yahoo! Finance: 1 views since Wednesday, July 9, 2008 at 07:00 AM
GlobeImmune, Inc. announced today the signing of a Cooperative Research and Development Agreement with the National Cancer Institute at the National Institutes of Health (NIH) to jointly develop products intended to treat a variety of cancers. GlobeImmune will utilize its proprietary Tarmogen® technology to develop multiple immunotherapy products expressing various cancer antigens provided by ...

Published in: Institutes